bis-stoppered porphyrin thread 10, and mono-stoppered thread
2:
7.82 (3H, s, ortho2), 7.79 (3H, s, para), 7.65 (1H, t, J 6, H23), 7.50
(1H, d, J 6, H24), 7.29 (2H, d, J 9, ND2), 7.19 (2H, d, J 6, ND1),
4.15 (2H, t, J 6, H26), 4.11 (2H, t, J 6, H33), 4.08 (4H, m, H45,
46), 4.01 (2H, t, J 6, H38), 3.59 (2H, t, J 6, H27), 3.53 (10H, m,
H28–32), 3.50–3.46 (12H, m, H39–44), 3.08 (2H, t, J 6, H35), 2.91
(2H, t, J 6, H34), 2.59 (4H, t, J 3, H36, 37), 1.66 (27H, s, t-butyl1),
1.46 (27H, s, t-butyl2), 1.24 (3H, t, J 6, H47), −3.84 (2H, s, H25).
10 (11.8 mg, 14%) as a purple solid (from MeOH–CHCl3); mp
184–187◦C; m/z (ES-MS) (C174H200N12O16): [M + 2H]2+ 1358.774
1
(calc. 1358.771); H NMR (300 MHz, CDCl3) d 8.87 (16H, m,
H2, 3, 7, 8, 12, 13, 17, 18), 8.17 (4H, d, J 6, H22), 8.17–8.15
(2H, hidden, H23), 8.12 (12H, ms, ortho), 7.90 (4H, d, J 9,
H21), 7.79 (6H, ms, para), 7.42 (4H, s, ND), 4.30 (4H, t, J 6,
H26), 4.05 (4H, t, J 6, H33), 3.70 (4H, t, J 6, H27), 3.60 (12H,
m, H28–30), 3.52 (8H, m, H31–32), 2.85 (4H, d, J 6, H34),
2.76 (4H, d, J 6, H35), 1.53 (108H, s, t-butyl), −3.19 (4H, s,
H25).
2,7-Bis(2-(2-(2-(2-(4-formylphenylcarboxy)-ethoxy)-ethoxy)-
ethoxy)-ethyl)benzo[lmn]-[3,8]phenanthroline-1,3,6,8-tetraone 20
This was synthesised by an analogous method to that used for
2, using dihydroxydiimide thread 5 (0.101 g, 1.64 × 10−4 mol),
4-carboxybenzaldehyde (0.079 g, 5.26 × 10−4 mol), dry DCM
(10 mL), dry Et3N (76 ll, 5.71 × 10−4 mol), EDC (0.160 g, 8.35 ×
10−4 mol), HOBT (0.088 g, 6.51 × 10−4 mol) and stirring for 7 d.
Upon removal of excess solvent, a yellow oil (144 mg, 99.5%) was
obtained, which was sufficiently pure for further reaction. (ESI-
MS) (C46H46N2O16): [M + Na]+ 905.276 (calcd. 905.275); 1H NMR
(300 MHz, CDCl3) d 10.02 (2H, s, H48), 8.65 (4H, s, ND), 8.13
(4H, d, J 9, H34), 7.88 (4H, d, J 9, H35), 4.43–4.36 (8H, m, H26,
33), 3.80 (8H, m, H27, 28), 3.65–3.64 (4H, m, H30), 3.63–3.56
(12H, m, H29, 31, 32).
2 (2.7 mg, 5%) as a purple solid (from MeOH–CHCl3); mp
100–104◦C; m/z (ESI-MS) (C108H127N7O17): [M + H]+ 1794.923
1
(calc. 1794.937); H NMR (300 MHz, CDCl3) d 8.85–8.80 (8H,
m, H2, 3, 7, 8, 12, 13, 17, 18), 8.26 (1H, br, H23), 8.20 (2H, d,
J 9, H22), 8.14–8.12 (6H, m, ortho), 7.95 (2H, d, J 9, H21), 7.88
(2H, d, J 8, ND2), 7.79–7.77 (3H, m, para), 7.76 (2H, d, J 8,
ND1), 4.38 (2H, t, J 5, H26), 4.23 (2H, t, J 6, H33), 4.17–4.11
(4H, m, H45, 46), 4.09 (2H, t, J 7, H38), 3.78 (2H, t, J 5, H27),
3.70–3.64 (10H, m, H28–32), 3.59–3.49 (12H, m, H39–44), 2.89
(2H, t, J 6, H34), 2.85 (2H, t, J 6, H35), 2.58–2.56 (4H, m, H36,
37), 1.54 (54H, s, t-butyl), 1.23 (3H, t, J 6, H47), −3.38 (2H, s,
H25).
5,10,15-Tris((3,5-di-tert-butyl)phenyl)-20-(4-
aminophenyl)porphyrinato)zinc(II) 21
2-(2-(2-(2-(2-(5,10,15-Tris((3,5-di-tert-butyl)phenyl)-20-(3-(3-car-
boxypropionoyl)phenyl)porphyrinyloxy)ethoxy)ethoxy)ethoxy)-
ethyl)-7-(2-(2-(2-(2-(3-ethoxycarbonyloxy)propionyloxy)ethoxy)-
ethoxy)ethoxy)ethyl)benzo[lmn]-(3,8)phenanthroline-1,3,6,8-
tetraone 3 and 2,7-bis-(2-(2-(2-(2-(5,10,15-tris((3,5-di-tert-
butyl)phenyl)-20-(3-(3-carboxypropionoyl)phenyl)porphyrinyloxy)-
ethoxy)ethoxy)ethoxy)ethyl)benzo[lmn]-(3,8)phenanthroline-
1,3,6,8-tetraone 11
Zinc was inserted into the free-base amino phenyl porphyrin using
the standard method (Zn(OAc)2–DCM–MeOH) t◦o give 21 as a
1
reddish purple solid (73 mg 98%); mp 299–302 C; H NMR
(300 MHz, CDCl3) d 8.96–8.91 (6H, m, H3, 7, 8, 12, 13, 17), 8.78
(2H, d, J 5, H2, 18), 8.11 (2H, d, J 2, ortho), 8.06 (4H, d, J 2,
ortho), 7.76 (1H, t, J 2, para), 7.72 (2H, t, J 2, para), 7.62 (2H, d,
J 8, H21), 5.63 (2H, br, H22), 1.50 (27H, s, t-butyl), 1.41 (27H, s,
t-butyl), −1.35 (1H, br, H23).
This was synthesised by a method similar to that described above
for 2, using 2,7-bis-(2-(2-(2-(2-(3-carboxypropionyloxy)eth-
oxy)ethoxy)ethoxy)ethyl)benzo[lmn]-(3,8)phenanthroline-1,3,6,8-
tetraone (23 mg, 2.81 × 10−5 mol), dry CHCl3 (13 mL), EtOH
(15 ll) dry Et3N (13 ll), EDC (13.5 mg, 7.04 × 10−5 mol),
HOBT (7.6 mg, 5.62 × 10−5 mol) and 5,10,15-tris((3,5-di-
tert-butyl)phenyl)-20-(3-hydroxyphenyl)porphyrin15 (60 mg,
6.20 × 10−5 mol). The crude product was purified by silica column
chromatography (1% MeOH–CHCl3) to give unreacted porphyrin
(10.5 mg, 17.5%), the bis-porphyrin thread unit 11 and 3:
2,7-Bis(2-(2-(2-(2-(4-(5-(phen-4-yl)10,15,20-tris((3,5-di-tert-
butyl)phenyl)porphyrinyl)-aminophenyl-4-benzylcarboxy)-ethoxy)-
ethoxy)-ethoxy)-ethyl)benzo[lmn]-[3,8]phenanthroline-1,3,6,8-
tetraone 12
Following the modified method outlined by Barney et al,25 to
a solution of naphthodiimide dialdehyde 20 (21.4 mg, 2.43 ×
10−5 mol), dry DCM (50 mL), and dry Et3N (10 ll, 7.17 × 10−5 mol)
was added NaBH3CN (4.6 mg, 7.29 × 10−5 mol). The solution
immediately went bright red, which was strongly indicative of
charge transfer complex formation. The mixture was equilibrated
for 60 min at RT after which time zinc amino phenyl porphyrin
21 (50 mg, 4.86 × 10−5 mol) and a solution of TiCl4 in DCM
(12.50 ll, 1.25 × 10−5 mol) were added. The reaction was then
stirred for 18 h before it was quenched with a THF solution of
NaBH3CN and the stirring was continued for a further 6 h. The
reaction mixture was then washed with 5 M NaOH, water (3×)
and dried (Na2SO4). Excess solvent was removed in vacuo. Multiple
purifications on preparative TLC silica plates (2% MeOH–DCM)
afforded the free-base derivative of amino phenyl porphyrin 21
(14 mg, 29.0% recovered), bis adduct 12 (5.8 mg, 4.3%), and the
corresponding mono-porphyrin adduct (16.8 mg, 14%).
11 as a purple solid (from MeOH–CHCl3) (17.2 mg, 23%); mp
182–184 ◦C; m/z (ESI-MS) (C174H198N10O18): [M + 2H]2+ 1359.759
(calc. 1359.755); 1H NMR (300 MHz, CDCl3) d 8.86–8.81 (16H,
m, H2, 3, 7, 8, 12, 13, 17, 18), 8.34 (6H, s, ortho1), 8.23 (2H, d, J
3, H21), 7.94 (2H, d, J 6, H22), 7.92 (6H, s, ortho2), 7.80 (6H, s,
para), 7.67 (2H, t, J 6, H23), 7.52 (2H, d, J 6, H24), 6.93 (4H, s,
ND), 4.22 (4H, t, J 6, H26), 4.00 (4H, t, J 6, H33), 3.61 (4H, t, J
6, H27), 3.48 (12H, m, H28–30), 3.43 (8H, m, H31–32), 3.01 (4H,
t, J 6, H35), 2.84 (4H, t, J 6, H34), 1.60 (54H, s, t-butyl1), 1.48
(54H, s, t-butyl2), −3.40 (4H, s, H25).
3 (3.3 mg, 6.6%) as a purple solid (from MeOH–CHCl3); mp
95–99 ◦C; m/z (ES-MS) (C108H126N6O18): [M + Na]+ 1817.904
1
(calc. 1817.903), [M + H]+ 1795.922 (calcd. 1795.921); H NMR
(300 MHz, CDCl3) d 8.85–8.79 (8H, m, H2, 3, 7, 8, 12, 13, 17,
18), 8.53 (3H, s, ortho1), 8.41 (1H, s, H21), 7.83 (1H, d, J 6, H22),
12 (from CHCl3–MeOH) mp 211–215 ◦C; m/z (ES-MS)
(C182H204N12O14): [M + Li]+ 2789 (calcd. 2788.56), [M + 2H]2+
This journal is
The Royal Society of Chemistry 2008
Org. Biomol. Chem., 2008, 6, 2534–2543 | 2541
©